Uncategorized

Biopharma’s Shopping Spree, Applied Crashes on Rejection, Skysona’s Safety Concerns, More

Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, Applied Therapeutics’ stock tanks 80% after govorestat is denied approval, Intra-Cellular Therapies seeks to expand Caplyta into major depressive disorder and the FDA investigates the safety of bluebird bio’s Skysona.

Biopharma’s Shopping Spree, Applied Crashes on Rejection, Skysona’s Safety Concerns, More Read More »

Scroll to Top